Results 11 to 20 of about 4,655,222 (236)

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring [PDF]

Acute Medicine & Surgery
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi, Reina Kawano, Takuto Tomokage, Ryo Ayata, Yasutaka Koga, Kotaro Kaneda, Motoki Fujita, Nanami Yamanaka, Naomasa Mori, Ryosuke Tsuruta   +9 more
doaj   +3 more sources

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]

PLoS Medicine
BackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch, Erzsébet Horváth-Puhó, Suzanne C Cannegieter, Nick van Es, Henrik T Sørensen   +4 more
doaj   +3 more sources

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland [PDF]

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +2 more sources

Discovery and development of Factor Xa inhibitors (2015–2022) [PDF]

Frontiers in Pharmacology, 2023
As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Wei Zheng, Wei Zheng, Xiaoqin Dai, Binyao Xu, Wei Tian, Jianyou Shi   +5 more
doaj   +2 more sources

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

Nature Communications, 2017
A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef, Koen M. Visscher, C. Ruben Vosmeer, Ka Lei Cheung, Pieter H. Reitsma, Daan P. Geerke, Mettine H. A. Bos   +6 more
doaj   +2 more sources

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study [PDF]

Research and Practice in Thrombosis and Haemostasis, 2021
Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp   +18 more
doaj   +6 more sources

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors [PDF]

Molecules, 2016
The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/
Milan Remko, Anna Remková, Ria Broer
doaj   +3 more sources

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +2 more sources

Expedited surgery does not increase transfusion rates for patients with geriatric hip fracture taking factor Xa inhibitors [PDF]

OTA International, 2023
. Objectives:. Geriatric patients who sustain hip fractures and are taking factor Xa inhibitors (Xa-I) experience surgical delay. Our institution developed a pharmacokinetic protocol to formally guide and expedite surgical timing for these patients.
Juntian Wang, MD, Paal Nilssen, BS, Julia Stone, BS, Kathleen Breda, MSN, BBA, RN, AGACNP-BC, ONP-C, Milton Little, MD, Charles Moon, MD, Carol Lin, MD   +6 more
doaj   +2 more sources

Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis [PDF]

Clinical and Applied Thrombosis/Hemostasis
Background Cancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population.
Amna Kamil MBBS, Sandhiya Prem Kumar MBBS, Rumaisa Zulfiqar MBBS, Eiman Araib MBBS, Bibi Samia Khan MBBS, Muhammad Saad Khan MBBS, Muhammad Mohsin Khan MBBS, Umaimah Naeem MBBS, Aminath Waafira MBBS   +8 more
doaj   +2 more sources